Genscript Biotech Corporation (FRA:G51)
Germany · Delayed Price · Currency is EUR 1.342
-0.005 (-0.33%)
At close: Jan 30, 2026
Genscript Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 828.1 | 594.49 | 560.48 | 625.7 | 490.1 | 390.85 | |
Revenue Growth (YoY) | 63.20% | 6.07% | -10.42% | 27.67% | 25.39% | 42.98% |
Cost of Revenue | 368.85 | 322.36 | 289.85 | 321.62 | 207.58 | 134.95 |
Gross Profit | 459.25 | 272.13 | 270.63 | 304.08 | 282.52 | 255.89 |
Selling, General & Admin | 217.35 | 202.5 | 186.96 | 350.81 | 302.48 | 197.68 |
Research & Development | 60.2 | 53.79 | 52.7 | 390.1 | 358.4 | 263.4 |
Operating Expenses | 279.83 | 262.84 | 244.44 | 742.06 | 661.81 | 460.44 |
Operating Income | 179.43 | 9.28 | 26.19 | -437.98 | -379.29 | -204.55 |
Interest Expense | -13.97 | -8.03 | -5.74 | -13.27 | -2.38 | -1.42 |
Interest & Investment Income | 25.95 | 28.89 | 22.58 | 13.22 | 6.55 | 8.01 |
Earnings From Equity Investments | -231.22 | -39.07 | -1.38 | - | - | -0.6 |
Currency Exchange Gain (Loss) | 1.84 | 1.57 | 2.54 | - | - | - |
Other Non Operating Income (Expenses) | 21.46 | 5.66 | 5.38 | -0.96 | -3.52 | -85.77 |
EBT Excluding Unusual Items | -16.51 | -1.71 | 49.58 | -438.98 | -378.63 | -284.33 |
Impairment of Goodwill | - | - | - | -11.48 | - | - |
Gain (Loss) on Sale of Investments | -18.45 | -123.58 | 130.97 | 18.77 | -138.73 | 2.43 |
Asset Writedown | -8.03 | -45.51 | -11.66 | - | - | - |
Pretax Income | -42.99 | -170.8 | 168.89 | -431.69 | -517.36 | -281.9 |
Income Tax Expense | 17.59 | 2.98 | 6.01 | -3.72 | 0.96 | -0.48 |
Earnings From Continuing Operations | -60.58 | -173.77 | 162.88 | -427.97 | -518.33 | -281.42 |
Earnings From Discontinued Operations | 3,107 | 3,029 | -518 | - | - | - |
Net Income to Company | 3,046 | 2,855 | -355.12 | -427.97 | -518.33 | -281.42 |
Minority Interest in Earnings | 65.16 | 106.59 | 259.64 | 201.12 | 159.62 | 76.48 |
Net Income | 3,112 | 2,962 | -95.48 | -226.85 | -358.71 | -204.95 |
Net Income to Common | 3,112 | 2,962 | -95.48 | -226.85 | -358.71 | -204.95 |
Shares Outstanding (Basic) | 2,140 | 2,121 | 2,109 | 2,097 | 2,031 | 1,901 |
Shares Outstanding (Diluted) | 2,198 | 2,178 | 2,109 | 2,097 | 2,031 | 1,901 |
Shares Change (YoY) | 4.08% | 3.27% | 0.58% | 3.28% | 6.83% | 2.53% |
EPS (Basic) | 1.45 | 1.40 | -0.05 | -0.11 | -0.18 | -0.11 |
EPS (Diluted) | 1.41 | 1.40 | -0.05 | -0.11 | -0.18 | -0.11 |
Free Cash Flow | 128.37 | -120.14 | -539.36 | -336.41 | -269.83 | -272.97 |
Free Cash Flow Per Share | 0.06 | -0.06 | -0.26 | -0.16 | -0.13 | -0.14 |
Gross Margin | 55.46% | 45.77% | 48.28% | 48.60% | 57.65% | 65.47% |
Operating Margin | 21.67% | 1.56% | 4.67% | -70.00% | -77.39% | -52.33% |
Profit Margin | 375.74% | 498.22% | -17.04% | -36.26% | -73.19% | -52.44% |
Free Cash Flow Margin | 15.50% | -20.21% | -96.23% | -53.76% | -55.06% | -69.84% |
EBITDA | 237.18 | 70.04 | 83.5 | -388.9 | -341.57 | -174.71 |
EBITDA Margin | 28.64% | 11.78% | 14.90% | -62.15% | -69.69% | -44.70% |
D&A For EBITDA | 57.75 | 60.75 | 57.3 | 49.08 | 37.72 | 29.84 |
EBIT | 179.43 | 9.28 | 26.19 | -437.98 | -379.29 | -204.55 |
EBIT Margin | 21.67% | 1.56% | 4.67% | -70.00% | -77.39% | -52.33% |
Effective Tax Rate | - | - | 3.56% | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.